Human Reproduction, pp. 1–1, 2021
doi:10.1093/humrep/deaa342

human reproduction

SUPPLEMENTARY DATA

Supplementary Table SXII Association of replicated SNPs with reduced ovarian function in the meta-analyses.

			Replication (PCL+SJLIFE) meta-analysis			Discovery + Replication (VEVO + PCL + SJLIFE) meta-analysis		
Variant	**Model**	**variant, interaction**	**OR (95% CI)**	**Direction**	***P*-value**	**OR (95% CI)**	**Direction**	***P*-value**
BRSK1	1	rs11668344	1.09 (0.83–1.45)	++	0.530	0.92 (0.72–1.17)	−++	0.480
rs11668344		CED: 0	1 (ref)		0.001	1 (ref)		2.0×10^{-5}
A > G		– >0–4000	1.23 (0.61–2.47)	+−	0.569	1.31 (0.80–2.21)	++−	0.309
		– ≥4000–8000	3.40 (1.94–5.96)	++	1.9×10^{-5}	3.73 (2.31–6.01)	+++	6.3×10^{-8}
		– ≥8000	3.90 (2.38–6.39)	++	6.2×10^{-5}	4.07 (2.59–6.39)	+++	1.0×10^{-9}
	2	rs11668344	0.82 (0.54–1.24)	−+	0.349	0.76 (0.53–1.11)	−−+	0.152
		CED: 0	1 (ref)		5.5×10^{-4}	1 (ref)		5.6×10^{-4}
		– >0–4000	0.58 (0.21–1.58)	−−	0.284	0.98 (0.46–2.09)	+−−	0.964
		– ≥4000–8000	3.42 (1.52–7.67)	++	2.8×10^{-4}	3.83 (1.90–7.74)	+++	1.8×10^{-4}
		– ≥8000	1.92 (0.97–3.79)	+−	0.059	1.92 (1.04–3.56)	++−	0.038
		SNP*CED: 0	1 (ref)		0.016	1 (ref)		0.018
		– >0–4000	3.27 (1.11–9.66)	+−	0.032	1.57 (0.71–3.47)	−+−	0.269
		– ≥4000–8000	1.04 (0.44–2.48)	+−	0.922	0.98 (0.48–2.02)	−+−	0.960
		– ≥8000	3.63 (1.66–7.95)	++	1.3×10^{-3}	3.81 (1.85–7.86)	+++	3.0×10^{-4}
FANCI	1	rs1054875	1.03 (0.78–1.37)	+−	0.844	1.02 (0.80–1.31)	++−	0.852
rs1054875		CED: 0	1 (ref)		0.001	1 (ref)		1.5×10^{-5}
A > T		– >0–4000	1.20 (0.59–2.41)	+−	0.617	1.27 (0.76–2.13)	++−	0.364
		– ≥4000–8000	3.46 (1.96–6.11)	++	1.8×10^{-5}	3.66 (2.27–5.90)	+++	9.8×10^{-8}
		– ≥8000	3.84 (2.34–6.30)	++	9.6×10^{-8}	4.02 (2.56–6.30)	+++	1.5×10^{-9}
	2	rs1054875	1.01 (0.65–1.56)	**+**−	0.977	0.85 (0.57–1.28)	−+−	0.432
		CED: 0	1 (ref)		0.002	1 (ref)		2.0×10^{-4}
		– >0–4000	0.88 (0.28–2.80)	**+**−	0.828	0.54 (0.23–1.24)	−+−	0.148
		– ≥4000–8000	5.29 (2.08–13.50)	**++**	4.7×10^{-4}	3.91 (1.83–8.33)	+++	4.1×10^{-4}
		– ≥8000	3.79 (1.83–7.83)	**++**	3.2×10^{-4}	3.77 (1.97–7.24)	+++	6.5×10^{-5}
		SNP*CED: 0	1 (ref)		0.869	1 (ref)		0.146
		– >0–4000	1.35 (0.46–3.96)	**++**	0.583	2.76 (1.17–6.53)	+++	0.021
		– ≥4000–8000	0.64 (0.29–1.40)	−−	0.264	0.92 (0.46–1.86)	+−−	0.823
		– ≥8000	1.03 (0.53–2.03)	**++**	0.925	1.14 (0.61–2.12)	+++	0.691
BRSK1	1	rs1172822	1.14 (0.86–1.50)	++	0.352	0.97 (0.77–1.23)	−++	0.808
rs1172822		CED: 0	1 (ref)		0.001	1 (ref)		2.0×10^{-5}
C > T		– >0–4000	1.23 (0.61–2.47)	+−	0.562	1.29 (0.77–2.17)	++−	0.333
		– ≥4000–8000	3.40 (1.94–5.97)	++	1.9×10^{-5}	3.68 (2.29–5.91)	+++	7.8×10^{-8}
		– ≥8000	3.92 (2.39–6.42)	++	5.8×10^{-8}	4.04 (2.57–6.34)	+++	1.2×10^{-9}
	2	rs1172822	0.89 (0.59–1.36)	−+	0.599	0.82 (0.57–1.20)	−−+	0.311
		CED: 0	1 (ref)		5.5×10^{-4}	1 (ref)		7.6×10^{-5}
		– >0–4000	0.66 (0.24–1.83)	−+	0.422	1.00 (0.46–2.16)	+−+	0.998
		– ≥4000–8000	3.69 (1.65–8.26)	++	1.5×10^{-3}	3.98 (1.96–8.06)	+++	1.3×10^{-4}
		– ≥8000	2.00 (1.02–3.94)	+−	0.045	1.91 (1.03–3.53)	++−	0.039
		SNP*CED: 0	1 (ref)		0.025	1 (ref)		0.025
		– >0–4000	2.61 (0.90–7.56)	+−	0.078	1.45 (0.67–3.17)	−+−	0.346
		– ≥4000–8000	0.93 (0.40–2.19)	+−	0.870	0.92 (0.45–1.88)	−+−	0.811
		– ≥8000	3.33 (1.55–7.16)	++	**2.0×10^{-3}**	3.71 (1.79–7.67)	+++	**4.2×10^{-4}**

CED, cyclophosphamide equivalent dose in mg/m^2; Het, Estimated heterogeneity variance; PanCareLIFE, PanCareLIFE cohort; St. Jude Lifetime, St. Jude Lifetime Cohort; VEVO, DCOG-LATER VEVO cohort.
Alt is coded. Model 1: adjusted for principal components, hormone usage, and CED score in four categories. Model 2: additional to Model 1 interaction term of variant*CED category. + = positive association of the SNP with reduced ovarian function in PCL and SJLIFE respectively. − = negative association of the SNP with reduced ovarian function in VEVO, PCL and SJLIFE, respectively. Pooled estimates based on the fixed effects model are presented.